Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
PLEASANTON, Calif., Dec. 17, 2018 /PRNewswire/ -- Responding to surging global interest in myopia management and its MiSight® 1 day contact lenses1, CooperVision's Specialty EyeCare Division has named two eye care industry veterans to newly-established professional services roles.
Elizabeth Lumb, BSc(Hons) MCOptom, FBCLA, has been appointed as Head of Professional Services, MiSight® 1 day, EMEA (Europe, Middle East and Africa) and Global Brand Manager for the lens. She joined the organization in 2013, serving as Professional Services Training Manager for Europe. Earlier in her career, she worked at Eurolens Research under the directorship of Professor Nathan Efron, conducting contact lens clinical research trials with findings presented at the American Academy of Optometry and BCLA conferences. Ms. Lumb was also a Senior Optometrist with Boots Opticians. She is based in the United Kingdom.
Chi Shing Fan, PD Optom, PhD, who led the test market introduction of MiSight® in Hong Kong, has been appointed as Professional Service and Commercial Lead, MiSight® & Specialty Business, Asia Pacific. He joined CooperVision in 2009, serving as Professional Services Director, Asia Pacific and as the region's Frequent Replacement Category Lead. Previously, he held regional professional services roles with Bausch + Lomb and CIBA Vision. Dr. Fan is based in Hong Kong.
"Closely partnering with eye care professionals is essential to advancing myopia management best practices, including embracing groundbreaking, proven technologies and educating parents," said Stuart Cockerill, Senior Director, Myopia Management at CooperVision. "For more than two decades, Fan and Liz have earned the respect of colleagues and clinicians across Asia Pacific and EMEA. Their new focus will further accelerate adoption of MiSight®, helping more children and their families benefit from this innovative approach."
The company has also recently appointed MiSight® Professional Services leads for the United Kingdom, France and Iberia. It intends to staff similar roles in Germany-Austria-Switzerland, Hong Kong and Singapore, aiding the establishment of myopia management best practices in those markets.
CooperVision® MiSight® is the world's first 1-day soft contact lens shown to substantially slow the progression of myopia in children. In a global multicenter study, it has been shown to reduce the progression of myopia by 59% (SE) and 53% (eye elongation) over three years when compared to a group of children wearing a single vision 1-day lens.2
The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 20503, bringing with it near- and long-term health challenges. Not only does it create blurred vision, but also increases the likelihood of conditions later in life such as glaucoma, cataract, retinal detachment and myopic maculopathy if not addressed.
1 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® is not approved in the United States.
2 Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 3-year results. Presented at: British Contact Lens Association Clinical Conference, Liverpool, England.
3 Holden et al, Ophthalmology 2016.
CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women's health, fertility and diagnostics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc.
firstname.lastname@example.org or +1-585-545-1815